5 recruiting, 4 terminated, 1 active not recruiting, 1 completed. 12 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 5, Terminated 4, Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 2 | 7 | Recruiting 4, Active not recruiting 1, Terminated 1, Unknown 1 |
Follow Relapsed Cancer: new trials by email Literature Review of Relapsed Cancer trials Research Report on Relapsed Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma LMP744, Conventional Surgery or Biopsy - Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1 / Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2026-07-15 | 2026-10-16 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 80 | 2024-11-27 | 2026-09-11 |
| Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D) - Cancer, Malignancy | Phase 1 | Recruiting | CytoMed Therapeutics Pte Ltd | 12 | 2024-11-19 | 2024-11-22 |
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody HST-1011, Cemiplimab - Solid Tumor, Adult, Relapsed Cancer | Phase 1 / Phase 2 | Active not recruiting | HotSpot Therapeutics, Inc | 77 | 2023-03-15 | 2025-02-04 |
| A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab - Multiple Myeloma, Relapsed Cancer | Phase 1 | Terminated | Anaveon AG | 4 | 2023-02-10 | 2024-02-12 |
| Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer BMF-219 - Non Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Terminated | Biomea Fusion Inc. | 13 | 2023-01-12 | 2025-02-07 |
| A Study to Investigate LYL797 in Adults With Solid Tumors LYL797 - Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 | Terminated | Lyell Immunopharma, Inc. | 57 | 2022-03-29 | 2025-07-01 |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Enasidenib, Venetoclax - Acute Myeloid Leukemia, Relapsed Cancer | Phase 1 / Phase 2 | Terminated | University Health Network, Toronto | 27 | 2020-11-05 | 2024-01-24 |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL Ibrutinib, Pembrolizumab, Rituximab - Primary Central Nervous System Lymphoma, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 37 | 2020-08-01 | 2026-10-21 |
| Lorlatinib Combinations in Lung Cancer Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation | Phase 1 / Phase 2 | Unknown | Massachusetts General Hospital | 96 | 2020-05-01 | 2021-03-10 |
| Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS CFI-400945 Fumarate - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | University Health Network, Toronto | 13 | 2018-05-25 | 2026-09-29 |
Recurrence (12) · Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (2) · Leukemia, Myeloid, Acute (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1) · Disease (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1)
Disease Attributes (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Hemic and Lymphatic Diseases (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (5) · Hematologic Diseases (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lung Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3)
Rituximab (2) · venetoclax (2) · Biopsy (1) · Crizotinib (1) · Dexamethasone (1) · Lenalidomide (1) · binimetinib (1) · cemiplimab (1) · daratumumab (1) · enasidenib (1) · glofitamab (1) · ibrutinib (1) · lorlatinib (1) · obinutuzumab (1) · pembrolizumab (1)
University Health Network, Toronto (2) · Anaveon AG (1) · BeOne Medicines (1) · Biomea Fusion Inc. (1) · CytoMed Therapeutics Pte Ltd (1) · Dana-Farber Cancer Institute (1) · HotSpot Therapeutics, Inc (1) · Jennifer R. Brown, MD, PhD (1) · Lyell Immunopharma, Inc. (1) · Massachusetts General Hospital (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (8) · Canada (3) · Germany (2) · Spain (2) · Australia (1) · Brazil (1) · China (1) · Denmark (1) · France (1) · Italy (1) · New Zealand (1) · Poland (1) · Singapore (1) · South Korea (1) · Switzerland (1)
Alison O'Neill, MD (1) · Anand D Jeyasekharan, Dr (1) · Eduard Gasal, MD (1) · Ibiayi Dagogo-Jack, MD (1) · Jackie Walling, MBChB, PhD (1) · Jennifer Brown, MD, PhD (1) · Jieming Zeng, Dr (1) · Karen Yee, M.D. (1) · Lakshmi Nayak, MD (1) · Sadhana Jackson, M.D. (1) · Steve Morris, MD (1) · Steven Chan, M.D. (1)